Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study.
Saved in:
| Title: | Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study. |
|---|---|
| Authors: | Porta C; Interdisciplinary Department of Medicine, University of Bari 'A. Moro', Bari, Italy. camillo.porta@gmail.com.; Division of Medical Oncology, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Piazzale G. Cesare 11, 70124, Bari, Italy. camillo.porta@gmail.com., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Taha T; Royal Marsden NHS Foundation Trust, London, UK., Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Bourlon MT; Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico - Universidad Panamericana, Escuela de Medicina, Mexico City, Mexico., Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Basso U; Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Molina-Cerrillo J; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Alonso-Gordoa T; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Myint ZW; Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA., Fornarini G; IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Buttner T; Department of Urology, University Hospital Bonn (UKB), Bonn, Germany., Park SH; Department of Hematology and Oncology, Sungkyunkwan University Samsung Medical Center, Seoul, South Korea., Ürün Y; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Pichler R; Department of Urology, Medical University of Innsbruck, Innsbruck, Austria., Rescigno P; Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK., Buchler T; Department of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic., Studentova H; Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic., Melichar B; Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic., Ansari J; Medical Oncology, Tawam Hospital, Al Ain, UAE., Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Kucharz J; Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland., Rizzo M; Division of Medical Oncology, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Piazzale G. Cesare 11, 70124, Bari, Italy., Rizzo A; IRCCS Istituto Tumori 'Giovanni Paolo II', 70124, Bari, Italy., Kopp RM; Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Monteiro FSM; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Oncology and Hematology Department, Hospital Sírio Libanês, Brasília, Brazil., Soares A; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Oncology Unit, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Bamias A; 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Santoni M; Medical Oncology Unit, Macerata Hospital, Macerata, Italy. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 May 09; Vol. 74 (7), pp. 196. Date of Electronic Publication: 2025 May 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-025-04019-x |
